Proteome Profiling of Experimental Autoimmune Encephalomyelitis Mouse Model and the Effect of a SUMO E1 Inhibitor

Area of Science:

• Neuroscience
• Immunology
• Proteomics

Background:

• Multiple sclerosis (MS) is a common neurodegenerative disease affecting the central nervous system.
• The experimental autoimmune encephalomyelitis (EAE) mouse model is used to study MS pathology.
• Molecular mechanisms underlying MS remain incompletely understood.

Purpose of the Study:

• To investigate molecular mechanisms in EAE using quantitative proteomics.
• To explore the role of SUMOylation in MS pathogenesis.
• To evaluate a SUMO E1 inhibitor as a potential MS treatment.

Main Methods:

• Quantitative proteomic analysis of brain and spinal cord tissues in EAE mice.
• Data-independent acquisition strategy for protein identification.
• Gene set enrichment analysis to identify biological processes.
• Administration of a selective SUMO E1 inhibitor (TAK-981) in EAE mice.

Main Results:

• Identified 744 differentially regulated proteins in the brain and 741 in the spinal cord of EAE mice.
• Associated protein changes with phagocytosis, lysosomal enzymes, inflammasome, complement activation, and synaptic loss.
• Revealed elevated SUMOylation processes in EAE, including increased SUMOylation-related enzymes and targets.
• TAK-981 suppressed global SUMOylation and significantly alleviated EAE symptoms.

Conclusions:

• SUMOylation plays a critical role in the progression of multiple sclerosis.
• Targeting SUMOylation with inhibitors like TAK-981 shows therapeutic potential for MS.
• This research enhances understanding of MS pathology and identifies a novel therapeutic strategy.